Parazelsus Group Overview January 2014
parazelsus 1. Parazelsus is a group focused primarily on marketing, sales and distribution services to manufacturers of healthcare and medical products. 2. We are an independent, privately owned business. Our experience and track record is linked with the successful development of Zuellig Pharma over the past 25 years. 3. With our focus on emerging regions in Europe, Asia and Latin America, our standards are transparent, professional and MNC oriented. 4. We are lean, profitable and expect to reach an annualised group revenue / portfolio of US$ 500 million by the end of 2015. 5. Our growth plan is supported by strategic partnerships such as the Godrej Group for South Asia. 6. Total number of employees in healthcare: 1,500
business structure Healthcare Marketing, Sales and Distribution Services Parazelsus Pazific Parazelsus Orient Parazelsus Americaz Investments Indonesia Pharmaceutical Marketing and Distribution (2008-2013) Pakistan Pharmaceutical Marketing and Distribution Mexico Pharmaceutical Marketing (2009-2012) Property Services DPRK Pharma Manufacturing Distribution and Retail India Pharmaceutical Contract Logistics and Contract Sales Thailand Facility Services Pest Control, Hygiene, Cleaning Afghanistan Pharmaceutical & Medical Marketing and Distribution Bangladesh, Sri Lanka Market entry projects
volume trend (at actual exchange rates)
india - pharmaceutical distribution Market entry August 2008. Established Parazelsus India Private Ltd. Strategic partnership with the Godrej Group. Pharmaceutical Distribution; focus on valueadding, specialty solutions. Cold Chain solution provider, targeting fast growing segment of biologicals. Covering top 20 locations across India. Validated by several MNCs. 3PL clients include Nicholas Piramal, J&J and Sanofi Pasteur. Parazelsus India Pvt Ltd Plant 14 P; Godrej Campus Pirojshanagar, Vikhroli Mumbai 400 079, India Tel +91 22 6796 3638 Fax +91 22 6796 1526 mail@parazelsus.co.in Web-based operating and CRM system. Developing single distribution solution model.
india contract sales organisation Market entry April 2013. Key clients include Novartis, GE Medical and several other global healthcare companies Strategic plan to become leading outsourcing solutions provider for sales & marketing to the Pharma Industry Reaching out to Physicians, Specialists, Hospital, Nursing Homes and Retail Pharmacies in order to drive product prescriptions and brand referrals through a trained and disciplined sales team. Scope of services include: Promote / Launch Market expansion and development Patient management Coaching for recruitment and training Acquired Interim Holding, majority shareholder of of CSMO Nextierr Pvt. Ltd. Parazelsus India Pvt Ltd Plant 14 P; Godrej Campus Pirojshanagar, Vikhroli Mumbai 400 079, India Tel +91 22 6796 3632 Fax +91 22 6796 1526 mail@parazelsus.co.in
pakistan - pharmaceutical sales & distribution Market entry January 2007. Acquired distribution infrastructure of Novartis Pakistan. Full range of marketing and distribution services. 13 branches 855 personnel 25,000 active customers. Exclusive distributor for Novartis, Sandoz, Bayer, Greenstar, Schering Plough and finalising terms with additional MNCs. Parazelsus Pakistan Pvt Ltd GSA House 95 East Wharf Road Karachi 75620, Pakistan Tel +92 21 286 3790 Fax +92 21 286 3794 mail@parazelsus.pk Centralised Oracle EBS IT system. ISO certification.
afghanistan medical sales & distribution Market entry May 2012. Acquired majority of Tradepoint Afghanistan. Range of marketing, sales and distribution services for medical and pharmaceuticals. 7 branches 50 personnel 200-300 sub-distributors Key focus on tender management for medical equipment, medical supplies and pharmaceuticals. Parazelsus Afghanistan Ltd 1st street Charah-e-Gul-e-surkh Kolola Poshta, Kabul, Afghanistan Tel +93 75 200 7000 mail@parazelsus.af Full range of services as agent for foreign manufacturers of pharmaceuticals and medical products. Cold chain facility.
indonesia - pharmaceutical distribution Market entry 2008 and exit in 2013 Acquired majority of PT DKSH Tunggal Well established, leading pharmaceutical distribution company; formed in 2006 as a joint venture between DKSH and Tunggal Sila Farma. Full range of marketing and distribution services 31 branches 760 personnel 25,000 active customers PT Parazelsus Indonesia 22 Menara Jamsostek, Jl Jend Gatot Subroto 38 Jakarta 12710, Indonesia Tel +62 21 522 8338 Fax +62 21 522 8337 mail@parazelsus.co.id 30 marketing and/or distribution agreements Centralised SAP system ISO certification
dprk - pharmaceuticals Market entry March 2007. Acquired majority of PyongSu J.V. Co. Ltd. Joint venture with Pyongyang Pharmaceuticals Factory. Pharmaceutical Manufacturing, Distribution and Retailing. Key service provider to WHO, IFRC and Unicef. 50 staff. Tablet and capsule manufacturing; 40 formulations; capacity of 300m tablets and capsules p.a. (1 shift) Pyongsu Pharma JV Co Ltd Pyongyang City Seongyo District, Daehungdong D.P.R. Korea Tel +850 2 381 5252 Fax +850 2 381 5248 mail@parazelsus.com 10 Pharmacies with a range of 370 Sku s. WHO-GMP certified.
mexico - pharmaceuticals Market entry August 2009 and partial exit 2012. Acquired majority of Lakeside de Mexico. Former subsidiary of Roche. Range of well established antibiotic products. Pharmaceutical marketing. Focus on life-cycle management. Expansion of product portfolio. Platform for introducing sales and distribution services. Expansion of geographic coverage in the Region. Lakeside de Mexico SA, de CV Prolongación Paseo de la Reforma 625-501 Col. Paseo de las Lomas México, 01330, D.F México Tel. +52 55 5292 8550 Fax. +52 55 5292 2706 ext 110 mail@lakesidepharma.com Experienced management team.
senior management team Name / Role Peter Zuellig; Founder Head of Strategy Markus Haefeli Managing Director Kaspar Kellerhals Director; Parazelsus Pakistan Yakub Thara Executive Director & CEO, Parazelsus Pakistan Bhuvan Asthana Head Operations; Parazelsus India Sharad Virmani Head of CSO; Parazelsus India Dr. Mehboob Shah Managing Director Parazelsus Afghanistan Remy Lardinois CEO; Pyongsu Pharma; DPRK Previous experience Executive Director, The Zuellig Group Joint CEO, The Zuellig Group CEO Australia, The Zuellig Group New Zealand Various positions at TZG (joined in 1981) COO Sonnenhof; private hospital group, Switzerland CEO Pharma Industries, a division of TZG; Hong Kong CFO Zuellig Pharma; Hong Kong Procter & Gamble; Switzerland VP Operations of Anugerah Pharmindo Lestari in Indonesia. From 1996 till 2010 he worked for Zuellig Pharma in Malaysia, Hong Kong, Indonesia and the Philippines. Prior to his joining Zuellig Pharma he was Logistics and IT Manager at Danzas Travel in Switzerland. Fellow member of Chartered Management Accountants (C.I.M.A. London). Over 4 decades of experience in the fields of Finance, Human Resource, Marketing and Distribution. Previously, he has worked for Tabba Heart Institute, Tapal Tea, Nandos Pakistan and Sandoz (now Novartis). Manager Contract Logistics, UTi Worldwide (India) Pvt. Ltd. responsible for business development, warehouse operation and primary and secondary distribution for various multinational clients. Former Head of CSO at Invida, responsible for Marketing, Sales, Business Development, SFE initiatives, Training & Recruitment with a field force in excess of 1,600 personnel. Previously VP Marketing & Sales with Comed Pharmaceuticals. Former Business Development Manager at Tradepoint Company in Afghanistan, primarily in the hospital sector. Dr. Shah holds an MD degree in Medicine from Nangarhar Medical University, Afghanistan. Business Development Manager with Hellmann Worldwide Logistics in South Korea and 6 years in mainland China, various industries. Degree in Chinese and Korean Studies from the University of London.
parazelsus Limited is an independent, pro-active investment and management group, founded by Peter Zuellig in 2005. The team at parazelsus includes industry and financial experts for its key investment areas - not alchemists. However, parazelsus understands very well how to generate value in the healthcare sector through an unconventional approach.